BRAIN TUMOR LIBRARY
Glioblastoma | Diagnosis
48



Home > Brain tumor library > Diffuse astrocytic and oligodendroglial tumors > Glioblastoma > Diagnosis

BIOMARKERS



Vaios EJ, Nahed BV, Muzikansky A, Fathi AT, Dietrich J.
Bone marrow response as a potential biomarker of outcomes in glioblastoma patients.
J Neurosurg. 2016 Oct 14:1-7. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Vietheer JM, Rieger J, Wagner M, Senft C, Tichy J, Foerch C.
Serum concentrations of glial fibrillary acidic protein (GFAP) do not indicate tumor recurrence in patients with glioblastoma.
J Neurooncol. 2017 Jul 17. doi: 10.1007/s11060-017-2565-y. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



CEREBELLAR GLIOBLASTOMA



Kikuchi K, Hiratsuka Y, Kohno S, Ohue S, Miki H, Mochizuki T.
Radiological features of cerebellar glioblastoma.
J Neuroradiol. 2016 Jul;43(4):260-5. doi: 10.1016/j.neurad.2015.10.006. Epub 2015 Dec 28.
Source | Abstract | Full text | Similar articles



EXTRACRANIAL METASTASIS



Garcia JR, Corbella C, Baquero M, Bassa P, Soler M.
Extracranial metastasis of multiforme glioblastoma detected by 11C-methionine brain PET/CT.
Rev Esp Med Nucl Imagen Mol. 2016 Oct 19. pii: S2253-654X(16)30066-X. doi: 10.1016/j.remn.2016.08.004. [Epub ahead of print] English, Spanish.
Source | Abstract | Full text | Similar articles



IMAGING



Chiang S.
Follow-Up Imaging: Molecular Imaging is Likely Best as a Single Modality, but Multimodality Imaging is the Future.
Front Neurol. 2015 Apr 24;6:74. doi: 10.3389/fneur.2015.00074. eCollection 2015. Review. No abstract available.
Source | Abstract | Full text | Similar articles




Galldiks N, Langen KJ.
Amino Acid PET - An Imaging Option to Identify Treatment Response, Posttherapeutic Effects, and Tumor Recurrence?
Front Neurol. 2016 Jul 28;7:120. doi: 10.3389/fneur.2016.00120. eCollection 2016.
Source | Abstract | Full text | Similar articles




Henker C, Kriesen T, Glass Ä, Schneider B, Piek J.
Volumetric quantification of glioblastoma: experiences with different measurement techniques and impact on survival.
J Neurooncol. 2017 Jul 28. doi: 10.1007/s11060-017-2587-5. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Huang RY, Neagu MR, Reardon DA, Wen PY.
Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response.
Front Neurol. 2015 Feb 23;6:33. doi: 10.3389/fneur.2015.00033. eCollection 2015.
Source | Abstract | Full text | Similar articles




Kolakshyapati M, Adhikari RB, Karlowee V, Takayasu T, Nosaka R, Amatya VJ, Takeshima Y, Akiyama Y, Sugiyama K, Kurisu K, Yamasaki F.
Nonenhancing peritumoral hyperintense lesion on diffusion-weighted imaging in glioblastoma: a novel diagnostic and specific prognostic indicator.
J Neurosurg. 2017 Mar 31:1-12. doi: 10.3171/2016.10.JNS161694. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




New PZ, Rosenfeld MR.
Editorial: Pitfalls in the Neuro-Imaging of Glioblastoma in the Era of Antiangiogenic and Immune-Targeted Therapy-Detecting Elusive Disease, Defining Response.
Front Neurol. 2017 Jul 3;8:311. doi: 10.3389/fneur.2017.00311. eCollection 2017.
Source | Abstract | Full text | Similar articles




Wong KK, Fung SH, New PZ, Wong ST.
Technical Pitfalls of Signal Truncation in Perfusion MRI of Glioblastoma.
Front Neurol. 2016 Aug 2;7:121. doi: 10.3389/fneur.2016.00121. eCollection 2016.
Source | Abstract | Full text | Similar articles



FLAIR IMAGING



Chang PD, Chow DS, Yang PH, Filippi CG, Lignelli A.
Predicting Glioblastoma Recurrence by Early Changes in the Apparent Diffusion Coefficient Value and Signal Intensity on FLAIR Images.
AJR Am J Roentgenol. 2017 Jan;208(1):57-65. doi: 10.2214/AJR.16.16234. Epub 2016 Oct 11.
Source | Abstract | Full text | Similar articles




Lasocki A, Gaillard F, Tacey M, Drummond K, Stuckey S.
Multifocal and multicentric glioblastoma: Improved characterisation with FLAIR imaging and prognostic implications.
J Clin Neurosci. 2016 Jun 21. pii: S0967-5868(16)00143-0. doi: 10.1016/j.jocn.2016.02.022. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



MAGNETIC RESONANCE IMAGING



Jovanovic M, Radenkovic S, Stosic-Opincal T, Lavrnic S, Gavrilovic S, Lazovic-Popovic B, Soldatovic I, Maksimovic R.
Differentiation between progression and pseudoprogresion by arterial spin labeling MRI in patients with glioblastoma multiforme.
J BUON. 2017 Jul-Aug;22(4):1061-1067.
Source | Abstract | Full text | Similar articles




Lasocki A, Tsui A, Gaillard F, Tacey M, Drummond K, Stuckey S.
Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma.
J Clin Neurosci. 2017 May;39:170-175. doi: 10.1016/j.jocn.2017.01.007. Epub 2017 Feb 14.
Source | Abstract | Full text | Similar articles




Ravikanth R.
Advanced Magnetic Resonance Imaging of Glioblastoma Multiforme.
J Neurosci Rural Pract. 2017 Jul-Sep;8(3):439-440. doi: 10.4103/jnrp.jnrp_423_16.
Source | Abstract | Full text | Similar articles



SUBTYPES



Chakraborty S, Priamo F, Boockvar JA.
Magnetic Resonance Imaging to Identify Glioblastoma Molecular Phenotypes.
Neurosurgery. 2016 Feb;78(2):N20-1. doi: 10.1227/01.neu.0000479895.10242.9d.
Source | Abstract | Full text | Similar articles




Itakura H, Achrol AS, Mitchell LA, Loya JJ, Liu T, Westbroek EM, Feroze AH, Rodriguez S, Echegaray S, Azad TD, Yeom KW, Napel S, Rubin DL, Chang SD, Harsh GR 4th, Gevaert O.
Magnetic resonance image features identify glioblastoma phenotypic subtypes with distinct molecular pathway activities.
Sci Transl Med. 2015 Sep 2;7(303):303ra138. doi: 10.1126/scitranslmed.aaa7582.
Source | Abstract | Full text | Similar articles



Newly diagnosed tumors



BCNU WAFERS



Murai S, Ichikawa T, Kurozumi K, Shimazu Y, Oka T, Otani Y, Shimizu T, Date I.
Quantitative analysis of brain edema in patients with malignant glioma treated with BCNU wafers.
J Clin Neurosci. 2016 Jul 21. pii: S0967-5868(16)30381-2. doi: 10.1016/j.jocn.2016.03.042. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



BIOPSY



Staller A.
Presumed Glioblastoma Multiforme: A Case for Biopsy Prior to Treatment.
Clin J Oncol Nurs. 2016 Feb;20(1):95-7. doi: 10.1188/16.CJON.95-97.
Source | Abstract | Full text | Similar articles



IMAGING



Toh CH, Castillo M.
Early-Stage Glioblastomas: MR Imaging-Based Classification and Imaging Evidence of Progressive Growth.
AJNR Am J Neuroradiol. 2016 Nov 17. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



PROGRESSION AND PSEUDOPROGRESSION



Wick W, Chinot OL, Bendszus M, Mason W, Henriksson R, Saran F, Nishikawa R, Revil C, Kerloeguen Y, Cloughesy T.
Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
Neuro Oncol. 2016 Aug 11. pii: now091. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



SERUM miRNAs



Regazzo G, Terrenato I, Spagnuolo M, Carosi M, Cognetti G, Cicchillitti L, Sperati F, Villani V, Carapella C, Piaggio G, Pelosi A, Rizzo MG.
A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas.
J Exp Clin Cancer Res. 2016 Jul 30;35(1):124. doi: 10.1186/s13046-016-0393-0.
Source | Abstract | Full text | Similar articles



Recurrent tumors



BEVACIZUMAB



Barajas RF Jr, Butowski NA, Phillips JJ, Aghi MK, Berger MS, Chang SM, Cha S.
The Development of Reduced Diffusion Following Bevacizumab Therapy Identifies Regions of Recurrent Disease in Patients with High-grade Glioma.
Acad Radiol. 2016 Sep;23(9):1073-82. doi: 10.1016/j.acra.2016.04.004. Epub 2016 Jul 18.
Source | Abstract | Full text | Similar articles




Bertaut A, Truntzer C, Madkouri R, Kaderbhai CG, Derangère V, Vincent J, Chauffert B, Aubriot-Lorton MH, Farah W, Mourier KL, Boidot R, Ghiringhelli F.
Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma.
Oncotarget. 2016 Jul 28. doi: 10.18632/oncotarget.10898. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Nguyen HS, Milbach N, Hurrell SL, Cochran E, Connelly J, Bovi JA, Schultz CJ, Mueller WM, Rand SD, Schmainda KM, LaViolette PS.
Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma.
AJNR Am J Neuroradiol. 2016 Aug 4. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



MRI



Ellingson BM, Chung C, Pope WB, Boxerman JL, Kaufmann TJ.
Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape.
J Neurooncol. 2017 Apr 5. doi: 10.1007/s11060-017-2375-2. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Yoo RE, Choi SH, Kim TM, Park CK, Park SH, Won JK, Kim IH, Lee ST, Choi HJ, You SH, Kang KM, Yun TJ, Kim JH, Sohn CH.
Dynamic contrast-enhanced MR imaging in predicting progression of enhancing lesions persisting after standard treatment in glioblastoma patients: a prospective study.
Eur Radiol. 2016 Dec 14. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



MULTIPARAMETRIC MRI



Nael K, Bauer AH, Hormigo A, Lemole M, Germano IM, Puig J, Stea B.
Multiparametric MRI for Differentiation of Radiation Necrosis From Recurrent Tumor in Patients With Treated Glioblastoma.
AJR Am J Roentgenol. 2017 Sep 27:1-6. doi: 10.2214/AJR.17.18003. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



(18)F FPPRGD2 PET/CT



Iagaru A, Mosci C, Mittra E, Zaharchuk G, Fischbein N, Harsh G, Li G, Nagpal S, Recht L, Gambhir SS.
Glioblastoma Multiforme Recurrence: An Exploratory Study of (18)F FPPRGD2 PET/CT.
Radiology. 2015 Nov;277(2):497-506. doi: 10.1148/radiol.2015141550. Epub 2015 May 12.
Source | Abstract | Full text | Similar articles



FDG PET/MR IMAGING COREGISTRATION



Leiva-Salinas C, Schiff D, Flors L, Patrie JT, Rehm PK.
FDG PET/MR Imaging Coregistration Helps Predict Survival in Patients with Glioblastoma and Radiologic Progression after Standard of Care Treatment.
Radiology. 2016 Oct 19:161172. doi: 10.1148/radiol.2016161172. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



RESPONSE ASSESSMENT



Gahrmann R, van den Bent M, van der Holt B, Vernhout RM, Taal W, Vos M, de Groot JC, Beerepoot LV, Buter J, Flach ZH, Hanse M, Jasperse B, Smits M.
Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.
Neuro Oncol. 2017 Feb 13. doi: 10.1093/neuonc/now311. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Huang R.
Response assessment in high-grade glioma: tumor volume as endpoint.
Neuro Oncol. 2017 Mar 30. doi: 10.1093/neuonc/nox035. [Epub ahead of print]
Source | Abstract | Full text | Similar articles